Table 1.
Between-trial variance estimates and model fit statistics from the considered models and priors in the first illustrative example on hepatitis C treatments for achieving sustained virological response (SVR)
| |
Between-trial variance estimates |
Model fit statistics |
|||
|---|---|---|---|---|---|
| Models | PEG-2A+RBV vs INF+RBV | PEG-2B+RBV vs INF+RBV | PEG-2B+RBV vs PEG-2A+RBV | pD | DIC |
|
Random-effects pair wise meta-analysis | |||||
| Frequentist (DerSimonian-Laird) |
0.642 |
0.000 |
0.036 |
-- |
-- |
| Frequentist (Hartung-Makimbi) |
0.580 |
0.017 |
0.021 |
-- |
-- |
| Bayesian (weakly informative) |
0.700 |
0.018 |
0.077 |
-- |
-- |
| Bayesian (frequentist informed) |
0.422 |
0.001 |
0.038 |
-- |
-- |
| Bayesian (empirically informed) |
0.091 |
0.024 |
0.052 |
-- |
-- |
|
Random-effects MTC models |
|
|
|
|
|
| Weakly informed variance models |
|
|
|
|
|
| Homogeneous variance model |
0.097 |
0.097 |
0.097 |
33.3 |
283.2 |
| Unrestricted variances |
1.046 |
0.017 |
0.103 |
32.8 |
277.7 |
| Exchangeable variances |
0.510 |
0.016 |
0.083 |
32.6 |
278.6 |
| Consistency variances structure |
0.225 |
0.024 |
0.164 |
32.9 |
280.2 |
| Moderately informed variance models |
|
|
|
|
|
| Frequentist informed priors |
0.677 |
0.011 |
0.047 |
30.9 |
275.6 |
| Empirically informed priors | 0.368 | 0.026 | 0.076 | 32.4 | 278.4 |
Abbreviations: PEG-2A (Peginterferon-2a); PEG-2B (Peginterferon-2b); INF (Interferon), RBV (Ribavirin).